Core Insights - Axogen, Inc. has received FDA approval for its Biologics License Application for AVANCE®, an acellular nerve allograft, allowing treatment for both adult and pediatric patients with peripheral nerve discontinuities [1][4] - H.C. Wainwright has set a price target of $39 for AXGN, indicating a potential price increase of approximately 15.73% from its current price of $33.70, influenced by the FDA approval [2] - The stock price of AXGN is currently at $33.74, reflecting a 2.69% increase, with a market capitalization of approximately $1.55 billion [3] Company Developments - The FDA's approval of AVANCE is a significant milestone for Axogen, enhancing its portfolio of surgical solutions and expected to drive interest in the stock [4] - The current trading volume of AXGN is 470,115 shares on the NASDAQ, indicating strong market interest following the recent FDA approval [4] Market Performance - AXGN's stock has shown volatility over the past year, with a high of $34.24 and a low of $9.22, reflecting its dynamic market presence [3] - The stock has risen by $0.885 today, with a trading range between $32.91 and $33.92 [3]